AGAdam E. S. Gymer

Adam E. S. Gymer

*This is an algorithmically generated author record based on publicly available information.

Adam E. S. Gymer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of New Catalytic Asymmetric Routes towards a Cost-Driving Building Block of Nirmatrelvir

    by Robert Szpera, Shanjun Huang, Harriet A. M. Fenton, William Waddington, Adam E. S. Gymer, Ian Moses, Julia Buck, Heather Ingram, Steven J. Fussell, Robert Walton, et al.

    Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease and is the active ingredient in PaxlovidTM. Nirmatrelvir presents a significant synthetic challenge, in no small part due to a cost-driving lactam containing fragment with two stereogenic centers. Our goal was to help decrease the cost of nirmatrelvir, by developing a scalable low-cost synthesis of this fragment, avoiding use of cryogenic conditions reported in the initial route. Herein we disclose three catalytic asymmetric routes to-wards this fragment, via i) chiral Lewis acid (copper) catalysis, ii) chiral Brønsted base organocatalysis and iii) chiral bifunctional hydrogen-bond-donor organocatalysis.